MEK162 (ARRY-162) --- MEK Inhibitor

Overview
Catalog #	bs-60080c-5mg-solid
Product Name	MEK162 (ARRY-162) --- MEK Inhibitor
Specifications
Storage Buffer	Powder
Storage Condition	Store in dry, dark place at -20C for 1 year.
Target
Product Information	Molecular Weight: 441.23 Formula: C17 H15 Br F2 N4 O3 CAS Number: 606143-89-9 InChi Key: ACWZRVQXLIRSDF-UHFFFAOYSA-N InChi: InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) Smiles: CN1C=NC2C(F)=C(NC3C=CC(Br)=CC=3F)C(=CC1=2)C(=O)NOCCO Purity: 98.0 Solubility: DMSO up to 100 mM Appearance: Solid Power. Shelf Life: 1.0 years
Description	MEK162 (ARRY-162) is a highly potent, selective, and orally bioavailable MEK inhibitor. It is a non-ATP competitive inhibitor of MEK1/2 (IC50 ~ 12 nM). It can inhibit pERK (IC50 ~11 nM) in cellular assays. At up to 20 µM it has no activity against a panel of 220 other kinases. MEK162 is especially potent at inhibiting cell proliferation of mutant B-Raf and Ras cell lines, such as HT29, Malme-3M, SK-MEL-2, COLO 205, SK-MEL-28 and A375 (IC50 from 30-250 nM). In vivo it has demonstrated efficacy in several xenograft tumor models in mice, including HT29, BxPC3, MIA PaCa2, A549, LoVo, Calu6, DU145 and COLO 205. In the HT29 and in the COLO 205 colon carcinoma models, dose-dependent inhibition of tumor growth (up to 75% TGI) was observed at doses ranging from 3 to 30 mg/kg, QD, PO for 21 days. Currently a phase I study of MEK162 in patients with biliary tract cancer is undergoing. MEK162 also shows inhibition of cytokine production such as IL-1, TNF and IL-6 in clinical trials for patients with rheumatoid arthritis.